Related by context. All words. (Click for frequent words.) 72 pharmacokinetic interactions 71 lenalidomide dexamethasone 70 mTOR inhibition 70 CYT# potent vascular disrupting 70 neratinib 69 mTOR inhibitors 69 LHRH antagonists 69 anti angiogenic agents 69 pharmacodynamic parameters 69 Xanafide 69 antiangiogenic therapy 69 CCX# 69 relapsed MM 69 multitargeted 69 liposomal doxorubicin 69 PSMA ADC 69 gefitinib Iressa 68 gemcitabine Gemzar 68 therapeutic regimens 68 CBLC# 68 bortezomib Velcade 68 anti angiogenic drugs 68 riociguat 68 paclitaxel Taxol ® 68 Panzem R NCD 68 antitumour 68 HuLuc# 68 oral prodrug 68 xenograft models 68 prednisone prednisolone 68 VEGF inhibition 68 Symadex 68 immunomodulation 68 MAGE A3 ASCI 68 Cardiotoxicity 68 molecular biomarkers 68 VEGF inhibitors 68 metaglidasen 68 immuno modulatory 68 antitumor effect 68 proton MR spectroscopy 68 Immunotherapeutic 68 trastuzumab Herceptin ® 68 preclinically 68 chemopreventive agents 68 pharmacodynamic PD 68 Thalomid ® 68 HDAC inhibition 67 calcineurin inhibitors 67 erlotinib Tarceva 67 LEP ETU 67 novel VDA molecule 67 antitumor efficacy 67 tumor hypoxia 67 Platinol ® cisplatin 67 docetaxel Taxotere ® 67 cMET 67 vivo potency 67 direct thrombin inhibitors 67 galiximab 67 efaproxiral 67 postoperative chemotherapy 67 cediranib 67 ENMD # 67 immune modulating 67 Pertuzumab 67 combinability 67 CRLX# 67 pyridostigmine 67 pharmacodynamic markers 67 monoclonal antibody therapies 67 fosbretabulin 67 Squalamine 67 flavopiridol 67 lipid lowering therapies 67 vidofludimus 67 somatostatin analogues 67 liver metastasis 67 skeletal metastases 67 Solazed TM 67 Azedra 67 Anthracycline 67 OMP #M# 66 Xelox 66 antiangiogenic drugs 66 small molecule tyrosine 66 Gastrointestinal Stromal Tumors 66 MEK inhibitors 66 dosing frequency 66 dexamethasone Decadron 66 candidate CRLX# 66 indibulin 66 anti androgens 66 intravenous cyclophosphamide 66 Triapine R 66 vinca alkaloid 66 potent antiproliferative 66 viral kinetics 66 Panzem 66 Mitoxantrone 66 hematopoietic cancers 66 Squamous 66 thalidomide Thalomid 66 salmeterol fluticasone 66 MGd 66 BRAF inhibitor 66 antithrombotics 66 enzastaurin 66 Interferon beta 66 eprotirome 66 dasatinib Sprycel 66 chemopreventive agent 66 ixabepilone 66 tolerability pharmacokinetics 66 tumor necrosis 66 allogeneic HSCT 66 radiochemotherapy 66 cardiac repolarization 66 cardiotoxic 66 standard chemotherapy regimens 66 antiangiogenesis 66 antimetabolite 66 intensive lipid lowering 66 antithrombotic therapies 66 EGFR HER2 66 myopathy rhabdomyolysis 66 albumin bound paclitaxel 66 HIF PH inhibitors 66 teriflunomide 66 metastatic neuroendocrine tumors 66 paclitaxel poliglumex 66 HCV protease inhibitors 66 Vidaza ® 66 Vidaza azacitidine 66 tubulin inhibitor 66 adecatumumab 66 antimitotic 66 antiplatelet therapies 66 trastuzumab Herceptin 66 Pemetrexed 66 corticosteroid dexamethasone 66 Pegylated Interferon 66 selective inhibition 66 potent anticancer 66 uric acid lowering 66 mechanistic insights 66 tigecycline 66 serum biomarkers 66 K ras mutations 66 BRAF inhibitors 66 GnRH agonists 66 tumor subtypes 66 treating neuropathic pain 66 NMDA antagonists 66 kidney urologic 66 adrenal suppression 66 rhITF 66 MMP inhibitors 66 liposomal amphotericin B 66 demonstrated antitumor activity 65 paclitaxel Taxol 65 immunosuppressive regimens 65 Safinamide 65 systemically administered 65 Deforolimus 65 microtubule inhibitor 65 eTag assays 65 ALA PDT 65 antiangiogenic activity 65 preclinical efficacy 65 CIMZIA ™ 65 lapatinib Tykerb 65 ganetespib 65 microtubule targeting 65 haematologic 65 amifostine 65 antioxidant supplementation 65 Vaxfectin TM 65 histologies 65 antiandrogen 65 cytotoxic therapies 65 Trofex 65 HuMax EGFr 65 tamoxifen Nolvadex ® 65 biodistribution 65 p# biomarker 65 PET tracers 65 HGS ETR2 65 neovascular diseases 65 evaluating tivozanib 65 erlotinib Tarceva ® 65 tanespimycin 65 doxorubicin HCl 65 PEGPH# 65 AChE inhibitors 65 dosage regimens 65 epigenetic therapies 65 murine models 65 tumor xenograft models 65 mecamylamine 65 anti amnesic 65 cytoprotective 65 TELINTRA 65 concurrent chemoradiation 65 molecularly targeted therapies 65 NEUGENE 65 KRAS status 65 liposomal formulation 65 infusional 65 Cytotoxic 65 cytostatic 65 LHRH agonists 65 Provecta 65 chemoprevention trials 65 cannabinor 65 intradermal injection 65 sorafenib Nexavar 65 Intravenous CP 65 Trofex TM 65 radiotherapy RT 65 pharmacodynamic profiles 65 Src inhibitors 65 MEK Inhibitor 65 gemcitabine carboplatin 65 HER2 expression 65 aspirin clopidogrel 65 pertuzumab 65 ritonavir boosted 65 EGFR TKIs 65 maximally tolerated 65 carcinoids 65 radioimmunotherapy RIT 65 cobiprostone 65 antitumor effects 65 YONDELIS 65 Panzem NCD 65 ALK inhibitors 65 prostanoid 65 clevidipine 65 FUSILEV enhances 65 TPI ASM8 65 DAVANAT 65 standard chemotherapy regimen 65 TLR antagonists 65 velafermin 65 OnDose TM 65 SERMs 65 antiangiogenic 65 SIRT1 activators 65 immunotoxins 65 steroid dexamethasone 65 IL# PE#QQR 65 mertansine 65 antithrombotic 65 antiemetics 65 Interferon Beta 65 cleavable linker 65 delafloxacin 65 Litx 65 TOCOSOL Camptothecin 65 EXPAREL ™ 65 inhaled bronchodilators 65 XmAb# 65 bronchodilatory 65 liposome formulation 65 Pyridorin 64 receptor tyrosine kinase inhibitor 64 Trastuzumab 64 IOP lowering 64 myelofibrosis polycythemia vera 64 overlapping toxicities 64 idarubicin 64 anti CD# antibodies 64 Interferon beta 1a 64 p# activation 64 systemic toxicity 64 oral picoplatin 64 molecularly targeted 64 solar keratoses 64 FDG PET imaging 64 Tumor Response 64 CINTREDEKIN BESUDOTOX 64 Cloretazine ® 64 pharmacodynamic properties 64 Nilotinib 64 ocular disorders 64 acadesine 64 CYP#A# inhibitors 64 unresectable tumors 64 favorable pharmacokinetic profile 64 peptide antigens 64 antiplatelet medications 64 APTIVUS 64 myeloproliferative diseases 64 MDS AML 64 biomarker identification 64 antiangiogenic agent 64 IFN beta 64 ATL/TV# 64 elotuzumab 64 IMA# 64 intratumoral 64 Hsp# inhibition 64 DACH platinum 64 pain palliation 64 BEXXAR Therapeutic Regimen 64 immunosuppressive agents 64 surgical debulking 64 etiologic 64 nodal metastasis 64 hoFH 64 OHR/AVR# 64 Erlotinib 64 systemic antifungal 64 BrachySil TM 64 oncologic outcomes 64 paclitaxel eluting stents 64 ADP receptor antagonist 64 invasive candidiasis 64 debulking surgery 64 imexon 64 Aplidin R 64 Zevalin consolidation 64 NATRECOR ® 64 pleiotropic 64 Anticalins ® 64 gemcitabine cisplatin 64 Immunomodulatory 64 Onconase 64 alvespimycin 64 AMPK activators 64 fibrate drugs 64 Tarceva TM 64 relapsed ovarian cancer 64 fluconazole resistant 64 idraparinux 64 chemosensitivity 64 cisplatin gemcitabine 64 cytotoxics 64 lipid lowering agents 64 PXD# 64 Zemiva TM 64 busulfan 64 Natalizumab 64 imatinib Gleevec 64 trastuzumab DM1 64 trastuzumab DM1 T DM1 64 #F FDG PET 64 JAK inhibitors 64 AEG# 64 potentially hepatotoxic 64 non selective NSAIDs 64 HER2 overexpression 64 immunostimulatory effects 64 topical NSAIDs 64 EGFRIs 64 receptor inhibitor 64 interferon gamma 1b 64 PEGylated interferon 64 florbetaben 64 renoprotective 64 pharmacologic treatments 64 Cloretazine R 64 antiplatelet drugs 64 HMG CoA reductase inhibitors 64 APTIVUS r 64 ESBA# 64 Anti VEGF 64 rituximab Rituxan 64 Inflammatory diseases 64 pancreatic prostate 64 intranasal delivery 64 CDDO Im 64 Velcade bortezomib 64 tumorigenicity 64 ARIKACE ™ 64 relapsed ALL 64 TTF therapy 64 GMX# 64 AV HALT 64 immunological responses 64 FOLFOX6 chemotherapy regimen 64 Aurora Kinase 64 antiepileptics 64 ritonavir boosted protease inhibitor 64 sargramostim 64 oral NSAIDs 64 cytoreduction 64 gastric adenocarcinoma 64 non nucleoside 64 Tyrima 64 Fludara ® 64 chemotherapy induced neutropenia 64 BCR ABL mutations 64 antitumoral 64 adjuvant trastuzumab 64 intranasal corticosteroids 64 recurrent glioblastoma multiforme 64 Sanofi Aventis Taxotere 64 including eniluracil ADH 64 triphendiol 64 plasma lipid 64 chlamydial 64 PRT# 64 protein kinase inhibitor 64 adjuvant therapies 64 bexarotene 64 vascular disrupting agents 64 TKI therapy 64 intra arterial chemotherapy 64 pro angiogenic 64 CYT# QbG# 64 Acute Ischemic Stroke 64 TroVax ® 64 topical retinoids 64 noscapine 64 heparanase 64 tumor histology 64 renal toxicity 64 probiotic supplementation 64 ancrod 64 PEP# [003] 64 glatiramer 64 Factor Receptor 64 vorinostat 64 MYCAMINE 63 CINQUIL 63 squalamine 63 intravenous bisphosphonates 63 topical calcineurin inhibitors 63 Fludarabine 63 Anticalins R 63 rEV# 63 ProSavin 63 angiographic outcomes 63 anti resorptive 63 Hormone Refractory Prostate Cancer 63 Thiovir 63 endometrial hyperplasia 63 CTAP# Capsules 63 HbF 63 dorzolamide 63 DXL TM 63 histone deacetylase inhibitor 63 VDAs 63 TNFa 63 predictive biomarkers 63 antianginal 63 cytotoxic agents 63 Doxil ® 63 macrolide antibiotics 63 caspofungin 63 cytotoxic effects 63 convenient dosing regimens 63 radiotherapeutic 63 estramustine 63 aplindore 63 Shark cartilage 63 F FDG PET 63 TO AVOID PREGNANCY WHILE 63 esophageal candidiasis 63 hepatocellular 63 neurosensory 63 Amplimexon 63 Neulasta ® 63 Telintra 63 infliximab Remicade 63 topical formulations 63 gastrointestinal stromal tumors GISTs 63 anti leukemic 63 anticancer treatments 63 genotypic resistance 63 levodopa therapy 63 EndoTAG TM -1 63 Antiangiogenic 63 pharmacological intervention 63 mapatumumab 63 Aplidin 63 mycophenolate mofetil 63 mGluR2 NAM 63 pomalidomide 63 LHRH 63 temsirolimus 63 Alocrest 63 Exherin TM 63 CA4P 63 effector function 63 budesonide foam 63 PEG SN# 63 nonpharmacologic 63 B7 H3 63 locoregional recurrence 63 micafungin 63 sorafenib tablets 63 rxRNA 63 S/GSK# 63 5 fluorouracil leucovorin 63 Smac mimetic 63 androgen suppression 63 Exelixis compounds 63 Angiolix 63 TLK# 63 pharmacological approaches 63 methylation markers 63 antagomirs 63 hERG 63 novel peptide 63 candidemia 63 sunitinib malate 63 plasmid DNA vaccine 63 antithrombotic agents 63 nanomolar 63 interferon ribavirin 63 metastatic lymph nodes 63 Vitaxin 63 PPAR gamma agonists 63 Xeloda capecitabine 63 Marqibo TM 63 neutropenic patients 63 farletuzumab 63 Estrogen Receptor 63 etanercept Enbrel 63 omega interferon 63 oral leukoplakia 63 hepatocellular carcinomas 63 Rigel R# 63 bleomycin 63 breast cancer subtypes 63 baseline LDH 63 inhaled corticosteroid therapy 63 liposomal formulations 63 novel anticancer 63 Solazed 63 pegylated interferons 63 opioid antagonists 63 VANOS TM 63 HGS ETR1 mapatumumab 63 fibrinolytic 63 paclitaxel Taxol R 63 nucleoside analog 63 taxane therapy 63 pegylated liposomal doxorubicin 63 bevacizumab Avastin Genentech 63 docetaxel Taxotere 63 PI3K inhibitors 63 Phase Ib II 63 Anavex #-# 63 Aflibercept 63 INCB# [003] 63 CLORETAZINE TM VNP#M 63 OnDose 63 acetonide FA 63 pharmacokinetic PK profile 63 AKT inhibitor 63 refractory prostate cancer 63 MyVax R 63 Anti angiogenic 63 zoledronate 63 intracranial hemorrhage ICH 63 anti dyslipidemic 63 Alequel 63 INCB# [001] 63 antiresorptive 63 Nanobodies ® 63 differential gene expression 63 cardiac perfusion 63 evaluating satraplatin 63 Valdoxan 63 immunomodulating 63 PGL# 63 FDG-PET/CT 63 Gefitinib 63 virologic responses 63 act synergistically 63 cisplatin resistant 63 pan HDAC inhibitor 63 DOS# 63 GAP #B# 63 dosimetric 63 corticosteroid therapy 63 enzyme inhibitors 63 OvaRex R 63 TLR9 agonists 63 anticancer therapy 63 either acutely decompensated 63 hyperphenylalaninemia HPA due 63 percutaneous biopsy 63 antineoplastic 63 GPx 63 chemoprotective 63 alpha blocker 63 vitamin D analogs 63 haematopoietic 63 talabostat 63 pyrazinamide 63 tezampanel NGX# 63 atrial tachyarrhythmias 63 H. pylori eradication 63 nephrotoxic 63 inhibit platelet function 63 mitochondrial toxicity 63 erythropoietic 63 oral JAK1 63 acitretin 63 vasodilators 63 CEQ# 63 potent cytotoxic 63 chemotherapy hormonal therapy 63 pre malignant lesions 63 gemcitabine Gemzar ® 63 ON #.Na 63 HIV HCV coinfected 63 Temsirolimus 63 ADAMTS# 63 metastatic colorectal 63 itraconazole Sporanox 63 TG# [003] 63 cinacalcet 63 neurotrophic 63 PI3K AKT 63 ClearPath HDR 63 RAS mutations 63 Darinaparsin 63 Phase 1b clinical trials 63 Virulizin ® 63 cetuximab Erbitux 63 inecalcitol 63 Th2 cytokines 63 Ophena TM 63 liposome encapsulated 63 antidepressant efficacy 63 immunomodulatory effects 63 fumagillin nanoparticles 63 plasma pharmacokinetics 63 thrombolytic agents 63 torsade de pointes 63 afamelanotide 63 indinavir 63 adjuvant cisplatin 63 KRAS mutation 63 hepatic fibrosis 63 PROSTVAC VF 63 ELACYT 63 subgroup analyzes 63 depsipeptide 63 pharmacodynamic endpoints 63 TLR agonists 63 lenalidomide Revlimid R 63 anti CD3 63 inhibitory effects 63 ChronVac C R 63 neuro protective 63 artemisinin derivative 63 RLY# 63 avosentan 63 targeted radiotherapeutic 63 #ME# 63 BrachySil 63 Mitomycin C 63 investigational monoclonal antibody 63 Evoltra ® 63 Zemplar Capsules 63 Archexin 63 TRV# [001] 63 H2 antagonists 63 scintigraphic 63 proteasome inhibitor 63 chemotherapeutic regimens 63 EUS FNA 62 Telatinib 62 Beta catenin pathway 62 mixed hyperlipidemia 62 denileukin diftitox 62 anti angiogenic therapy 62 noninfectious uveitis 62 G#DT 62 anti angiogenic therapies 62 DCVax R 62 axitinib 62 Topical corticosteroids 62 CR# vcMMAE 62 selective modulator 62 fusion enhancers 62 oral taxane 62 transgene expression 62 forodesine 62 AERx ® 62 Enzastaurin 62 insulin sensitizing 62 rALLy 62 oral Hycamtin 62 convenient dosing regimen 62 Tasimelteon 62 β blockers 62 immunomodulatory therapy 62 immunomodulatory properties 62 CG# [003] 62 thetreatment 62 efficacy tolerability 62 carbohydrate polymers 62 TYSABRI natalizumab 62 verteporfin 62 EP #R 62 antisense inhibitors 62 anti atherogenic 62 GAMMAGARD 62 endothelin antagonists 62 Hepatocellular Carcinoma HCC 62 ocular allergy 62 JAK2 inhibitors 62 apoptosis inducing 62 antimetabolites 62 glycosylated hemoglobin HbA1c 62 pheochromocytoma 62 trabectedin 62 resolvins 62 Meta analyzes 62 SIRT1 activation 62 Onrigin 62 EEG abnormalities 62 QUADRAMET R 62 hypervascular tumors 62 letrozole Femara 62 somatostatin analogs 62 endocrine therapies 62 oral gallium 62 RhuDex TM 62 Fulvestrant 62 Gleevec resistant 62 Azedra ™ 62 MetMAb 62 antitumour activity 62 LHRH receptor positive 62 DXL# 62 Carfilzomib 62 HGS# 62 NSAID induced GI 62 Randomized trials 62 antiarrhythmic 62 benign neoplasms 62 anticancer therapies 62 PSN# [002] 62 rosuvastatin #mg 62 Photodynamic therapy 62 Xeloda ® 62 thromboembolic disease 62 alkylating agent 62 Prolongs Survival 62 Intravail ® 62 Lauriad 62 anticholinergic agents 62 DNA methylation markers 62 metaplasia 62 transarterial chemoembolization 62 mucinous 62 HIF PHIs 62 anthracycline chemotherapy 62 preoperative chemotherapy 62 bendamustine 62 Epanova 62 beta interferons 62 pulmonary metastases 62 doxorubicin docetaxel 62 primidone 62 SILENOR 62 haemostatic 62 Fluorouracil 62 Solorel TM 62 complement inhibitor eculizumab 62 metastatic malignant 62 ALK inhibitor 62 peak plasma concentrations 62 immune modulatory 62 SNT MC# 62 enoximone 62 BAL# [002] 62 EGFR tyrosine kinase inhibitors 62 abacavir Ziagen 62 intravascular hemolysis 62 inhaled iloprost 62 hematologic abnormalities 62 cytoreductive surgery 62 NNRTI resistant virus 62 chromosomal rearrangement 62 bovine thrombin 62 Locked Nucleic Acid LNA 62 metastatic RCC 62 antithrombotic therapy 62 orally bioavailable mimics 62 epithelial tumors 62 platelet inhibitor 62 NB S# strontium malonate 62 Campath alemtuzumab 62 vitamin B# folic acid 62 mAbs 62 pleiotropic effects 62 antiproliferative effects 62 psychopharmacologic 62 cranial radiation 62 Smac mimetics 62 proteasome inhibitors 62 DAC HYP 62 Dasatinib 62 kinase inhibition 62 immunomodulators 62 imetelstat 62 nab paclitaxel 62 PDE4 inhibitors 62 thoracoscopic lobectomy 62 neuroprotective properties 62 radezolid 62 Capecitabine 62 seminomas 62 biologic therapeutics 62 panitumumab Vectibix 62 cilengitide 62 topical ophthalmic 62 DFMO 62 Anticalins 62 bevacizumab Avastin 62 ARB telmisartan 62 biochemical abnormalities 62 plasma kallikrein inhibitor 62 Quinamed 62 Phase Ib study 62 Inhalation Solution 62 paclitaxel cisplatin 62 pharmacologic intervention 62 EGFR pathway 62 inotropic 62 lymphomas leukemias 62 Bevacizumab 62 serum cortisol 62 androgen deprivation 62 lymphoid tumors 62 panobinostat 62 Blinatumomab 62 nicardipine 62 IMC #B 62 CaPre TM 62 Radiofrequency ablation 62 AQ4N 62 Diovan HCT 62 antidiabetic 62 prophylactic anticoagulation 62 clobazam 62 molecular determinants 62 pharmacogenetic testing 62 Surgical resection 62 small molecule activators 62 NovaBay Aganocide compounds 62 oxaliplatin Eloxatin 62 paricalcitol 62 BioVant 62 neovascular 62 esophageal gastric 62 STRIDE PD 62 Retreatment 62 Preclinical studies suggest 62 multicentric 62 TNF alpha antagonist 62 INTEGRILIN ® 62 ritonavir boosting 62 Hematologic 62 PI3K/Akt pathway inhibitor 62 ceftazidime 62 molecular abnormalities 62 Phase #/#a trial 62 EGFR antibodies 62 postoperative mortality 62 induce remission 62 PROSTASCINT R 62 potent suppressor 62 androgen ablation 62 investigational therapies 62 Lisofylline LSF 62 Octreolin 62 Antitumor Activity 62 non nucleoside HCV 62 goserelin 62 oral anticoagulants 62 NMDA antagonist 62 AGHD 62 GRNCM1 62 PC# cells 62 Elotuzumab 62 prostate cancer CaP 62 OncoVEX 62 proliferative disorders 62 Solulin 62 Radical prostatectomy 62 biliary tract cancer 62 conventional DMARDs 62 anti tubercular 62 Cytarabine 62 INS# [001] 62 anti angiogenic agent 62 locoregional 62 antidiabetic drugs 62 Glucocorticoids 62 JAK2 inhibitor 62 Lisofylline 62 anticancer activity 62 rosuvastatin Crestor 62 HDACi 62 rBChE 62 TLR8 agonist 62 multimodality therapy 62 prognostic indicators 62 chemoradiation therapy 62 metastatic bone 62 griseofulvin 62 orally dosed 62 PDGF receptor 62 tiuxetan 62 MYLOTARG 62 ONCONASE R 62 hypofractionated 62 biotherapy 62 oral deforolimus 62 trastuzumab Herceptin R 62 Romidepsin 62 PSA nadir 62 Paliperidone 62 arsenic trioxide ATO 62 pharmacological interventions 62 perioperative morbidity 62 AZILECT ® 62 prospective multicenter study 62 catheter occlusion 62 Taxol ® 62 LEUKINE 62 immunofluorescence staining 62 candidates Azedra TM 62 immunomodulatory 62 Trandolapril 62 cisplatin chemotherapy 62 azacytidine 62 gallium nitrate 62 Dacogen decitabine 62 antiproliferative 62 OMNARIS HFA 62 Golimumab 62 metastatic castration resistant 62 HSP# inhibitor 62 breast endometrial 62 PI3K/mTOR 62 endometrial carcinoma 62 mutated K ras 62 urate lowering 62 nomograms 62 PROLARIS 62 tezampanel 62 oral levofloxacin 62 differentiated thyroid 62 ZOLINZA 62 EndoTAGTM 1 62 laser photocoagulation 62 refractory metastatic 62 Dapagliflozin 62 Targretin 62 malignant ascites 62 Candida infection 62 protein tyrosine phosphatase 62 biodistribution studies 62 selective agonists 62 nucleoside analogues 62 analgesic medications 62 HYLENEX recombinant 62 5 HT2A 62 systemic corticosteroid 62 CHOP chemotherapy 62 LAB CGRP 62 Allovectin 7 ® 62 favorable pharmacokinetic 62 pharmacodynamic effects 62 Phase #b/#a clinical 62 Tyrosine Kinase Inhibitor 62 TMP SMX 62 precursor lesions 62 oral antidiabetic medication 62 transdermal estrogen 62 ABVD 62 electrophysiologic 62 Taxotere docetaxel 62 Nexavar sorafenib 62 flutamide 62 antihormonal 62 cytotoxic chemotherapy 62 EndoTAG 62 phototoxicity 62 bardoxolone methyl 62 hypoxic tumors 62 MP4OX 62 motexafin gadolinium 62 Oral corticosteroids 62 Biomerk Tumorgrafts 62 calcineurin inhibitor 62 fenretinide